Precision BioSciences, Inc., a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, announced that it has been selected to deliver a late-breaking oral presentation at the Liver Meeting 2025. The oral presentation will feature new PBGENE-HBV data from the first two cohorts of the Phase 1 ELIMINATE-B Trial. The Liver Meeting 2025, which is the 76th annual meeting of the American Association for the Study of Liver Diseases, will take place in Washington, D.C., from November 7-11, 2025.
Health Technology Insights: Venus Concept Announces $11.48 Million Debt-to-Equity Exchange Transaction
Details of the presentation:
Abstract title: PBGENE-HBV, a First-in-class Gene Editing Therapy for Chronic Hepatitis B, Demonstrates Safety and Antiviral Activity in Early Cohorts
Publication number: 5017
Type of presentation: Late-breaking oral presentation
Authors: Man-Fung Yuen, Alina Jucov, Edward Gane, Emily B. Harrison, Andrew Van Cott, Abhishek Chandiramani, Neil Leatherbury, John Fry, Jeff Smith, Cassandra L. Gorsuch, Stanley Frankel, Mark Sulkowski
Date and time: Monday, November 10th 5:30PM-6:00PM EST
About PBGENE-HBV (Viral Elimination Program):
PBGENE-HBV is Precision’s wholly owned in vivo gene editing program under investigation in a global first-in-human clinical trial, which is designed to potentially cure chronic hepatitis B infection. Currently, it is estimated that 300 million people worldwide are afflicted with chronic hepatitis B. PBGENE-HBV is the first and only potentially curative gene editing program to enter clinical investigation that is specifically designed to eliminate cccDNA and inactivate integrated HBV DNA. Lipid nanoparticle technology for PBGENE-HBV has been provided by Acuitas Therapeutics, Inc.
Health Technology Insights: Corey A. Collins Promoted to CEO of Tekton Research to Lead Next Era of Growth
About Hepatitis B:
Hepatitis B is a leading cause of morbidity in the US and death globally, with no curative options currently available for patients. Despite the availability of approved antiviral therapies, an estimated 300 million people globally and 1-2 million people in the US are estimated to have chronic hepatitis B infection. An estimated 15% to 40% of patients with HBV infections may develop complications, such as cirrhosis, liver failure, or liver cancer (hepatocellular carcinoma), which account for the majority of HBV-related deaths.
Chronic hepatitis B infection is primarily driven by persistence of HBV cccDNA, which enables continued viral replication, and integration of HBV DNA into the human genome in liver cells. Current treatments for patients with chronic hepatitis B include agents that result in long-term viral suppression as indicated by reduction of circulating HBV DNA, but these therapies do not eradicate HBV cccDNA, rarely lead to functional cure, and require lifelong administration.
About the ELIMINATE-B Trial:
The Phase 1 ELIMINATE-B study is currently enrolling HBeAg-negative chronic hepatitis B patients at world-class sites in Moldova, Hong Kong, New Zealand, and the U.S. The goal of the study is to define the optimal dose and number of dose administrations for safely eliminating cccDNA and inactivating integrated HBV DNA. With regulatory approval already granted, Precision expects to expand the study to clinical trial sites in the U.K. and continue accelerating recruitment and evaluation of a genetically diverse patient population in the Phase 1 study.
Health Technology Insights: BioStem Renews Sponsorship with Florida Panthers Program
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – businesswire
